Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

GLP-1 Diabetes Drug Mounjaro Gets FDA Okay to Reduce Heart Attack and Stroke

29 August 2026 · By · Wire by Fusion42

Published

29 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at everydayhealth.com →

◆ Verified

Fusion42 · 29 August 2026 · Fusion42 review

The FDA has approved the diabetes drug Mounjaro for reducing the risk of heart attack and stroke in patients, expanding its use beyond blood sugar control.

This Wire brief sits within Fusion42's coverage of Health, and 20 sources have reported it between 28 Aug 2026 and 1 Sep 2026.

◆ ◆ The Wire takeaway

Diabetes drug makers gain a new chance to compete in cardiovascular treatment, shifting the market for combination therapies you can build or sell alongside Mounjaro.

◆ Coverage

20 sources · first reported 28 Aug 2026 · latest 1 Sep 2026

◆ Topics

Healthfda-approvaldiabetescardiovascular-riskdrug-expansion